AtaiBeckley (ATAI) Other financing activities (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly Other financing activities of $821000.0 for Q1 2026, up 106.8% year-over-year from $397000.0 in Q1 2025, and up 106.8% quarter-over-quarter from $397000.0 in Q1 2025.
Analysis
AtaiBeckley (ATAI) Other financing activities (2021 - 2026) Analysis & Trends
AtaiBeckley has reported Other financing activities for 5 years, with the latest figure at -$11.5 million in Q3 2025.
- Quarterly Other financing activities fell 3442.64% year-over-year to -$11.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $535000.0 (up 604.72% YoY) and the FY2024 annual result came in at $535000.0, up 435.0% from the prior year.
- Other financing activities for Q1 2026 stood at $821000.0, up from $397000.0 in the prior quarter.
- The five-year high for Other financing activities was $821000.0 in Q1 2026, with the low at $397000.0 in Q1 2025.
- A 5-year average of $209214.3 and a median of $169000.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 3320.86% in 2025, down 3442.64% in 2025.
- Over 5 years, Other financing activities stood at -$534000.0 in 2021, then soared by 123.03% to $123000.0 in 2022, then plunged by 186.18% to -$106000.0 in 2023, then soared by 604.72% to $535000.0 in 2024, then slumped by 2258.69% to -$11.5 million in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered -$11.5 million, $11.2 million, and $397000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.64 Mn |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | 9.95 Mn |
| Jun 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 11.15 Mn |
| Mar 31, 2025 | 397,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Mar 31, 2023 | 206,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | 117,000.00 |
| Mar 31, 2022 | 132,000.00 |
| Dec 31, 2021 | 401,000.00 |
| Mar 31, 2021 | 534,000.00 |